| [1] |
HSU C M, LI N C, LACSON E K J R, et al. peritoneal dialysis technique survival:a cohort study[J]. Am J Kidney Dis, 2024, 84(3):298-305. doi:10.1053/j.ajkd.2024.03.012.
|
| [2] |
DRIEHUIS E, ESHUIS M, ABRAHAMS A, et al. Automated peritoneal dialysis versus continuous ambulatory peritoneal dialysis for people with kidney failure[J]. Cochrane Database Syst Rev, 2024, 9(9):CD006515. doi:10.1002/14651858.CD006515.pub2.
|
| [3] |
XU Z, XU X, ZHU X, et al. Attention-based deep learning model for prediction of major adverse cardiovascular events in peritoneal dialysis patients[J]. IEEE J Biomed Health Inform, 2024, 28(2):1101-1109. doi:10.1109/JBHI.2023.3338729.
|
| [4] |
KWON Y E, AHN S Y, KO G J, et al. Impact of uric acid levels on mortality and cardiovascular outcomes in relation to kidney function[J]. J Clin Med, 2024, 14(1):20-33. doi:10.3390/jcm14010020.
|
| [5] |
LI S, HAN X, SONG J, et al. Mechanism of action and risk prediction of adiponectin in cardiovascular diseases[J]. Front Biosci(Landmark Ed), 2024, 29(8):286-302. doi:10.31083/j.fbl2908286.
|
| [6] |
吴楠, 吴超然, 陈曦, 等. 肺部超声B线数量与腹膜透析患者水肿指数,NT-proBNP相关性及在容量超负荷中的评估效能[J]. 临床误诊误治, 2024, 37(8):51-57.
|
|
WU N, WU C R, CHEN X, et al. Correlation between the number of lung ultrasound B-lines and edema index,NT-proBNP in patients undergoing peritoneal dialysis and its eval-uation efficacy in volume overload[J]. Clin Misdiag Misther, 2024, 37(8):51-57. doi:10.3969/j.issn.1002-3429.2024.08.011.
|
| [7] |
赵振平, 王丽敏. 中国慢性肾脏病防控面临的挑战和建议[J]. 中华流行病学杂志, 2025, 46(1):9-17.
|
|
ZHAO Z P, WANG L M. Challenges and suggestions for the prevention and control of chronic kidney disease in China[J]. Chin J Epidemiol, 2025, 46(1):9-17. doi:10.3760/cma.j.cn112338-20240722-00448.
|
| [8] |
LI D, LIU R, QI X, et al. A predictive model based on serum bicarbonate for cardiovascular events after initiation of peritoneal dialysis[J]. Ren Fail, 2024, 46(2):2422428. doi:10.1080/0886022X.2024.2422428.
|
| [9] |
WANG Y, ZHOU C, MA X, et al. The impact of angiotensin-receptor neprilysin inhibitors on cardiovascular events and solute transport function in peritoneal dialysis patients:a multicenter retrospective controlled study[J]. Ren Fail, 2024, 46(2):2431637. doi:10.1080/0886022X.2024.2431637.
|
| [10] |
MENDOZA CARRERA F, VÁZQUEZ RIVERA G E, LEAL CORTÉS C A, et al. Uric acid correlates with serum levels of mineral bone metabolism and inflammation biomarkers in patients with stage 3a-5 chronic kidney disease[J]. Medicina(Kaunas), 2024, 60(12):2081-2094. doi:10.3390/medicina60122081.
|
| [11] |
MYASOEDOVA V A, BERTOLINI F, VALERIO V, et al. The role of adiponectin and leptin in fibro-calcific aortic valve disease:A systematic review and meta-analysis[J]. Biomedicines, 2024, 12(9):1977-1988. doi:10.3390/biomedicines12091977.
|
| [12] |
ZHAO G, ZHENG Y, TIAN N, et al. The relationship between serum uric acid and gastrointestinal bleeding in peritoneal dialysis patients:a propensity score analysis[J]. Ren Fail, 2024, 46(2):2407881. doi:10.1080/0886022X.2024.2407881.
|
| [13] |
YANG H S, KIM S N, RO J H, et al. Adiponectin and all-cause mortality in patients with chronic kidney disease:A systematic review and meta-analysis[J]. Metabolites, 2025, 15(4):230-245. doi:10.3390/metabo15040230.
|
| [14] |
ABO EL FOTOH W M, EL MASHAD G M. Elevated baseline adiponectin level predicting an increased risk of disease activity in idiopathic nephrotic syndrome and chronic kidney disease in children[J]. Minerva Pediatr (Torino), 2023, 75(3):410-416. doi:10.23736/S2724-5276.17.04927-1.
|
| [15] |
YUAN J, ZHAO J, QIN Y, et al. Association of serum uric acid with all-cause and cardiovascular mortality in chronic kidney disease stages 3-5[J]. Nutr Metab Cardiovasc Dis, 2024, 34(6):1518-1527. doi:10.1016/j.numecd.2024.01.032.
|
| [16] |
ZHANG Y, LIAN Q, NIE Y, et al. Causal relationship between serum uric acid and cardiovascular disease:A mendelian randomization study[J]. Int J Cardiol Heart Vasc, 2024, 54:101453. doi:10.1016/j.ijcha.2024.101453.
|
| [17] |
LV Y L, LIU Y M, DONG K X, et al. Association of serum uric acid with all-cause and cardiovascular mortality in cardiovascular disease patients[J]. Sci Rep, 2024, 14(1):26675-26688. doi:10.1038/s41598-024-76970-1.
|
| [18] |
GIANOPOULOS I, MANTZOROS C S, DASKALOPOULOU S S. Adiponectin and adiponectin receptors in atherosclerosis[J]. Endocr Rev, 2025, 46(1):1-25. doi:10.1210/endrev/bnae021.
|
| [19] |
YUE H, ZHANG Q, CHANG S, et al. Adiponectin protects against myocardial ischemia-reperfusion injury:a systematic review and meta-analysis of preclinical animal studies[J]. Lipids Health Dis, 2024, 23(1):51-69. doi:10.1186/s12944-024-02028-w.
|